

# Tim R Cressey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6274453/publications.pdf>

Version: 2024-02-01

135  
papers

7,386  
citations

186254

28  
h-index

69246

77  
g-index

140  
all docs

140  
docs citations

140  
times ranked

3900  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. <i>Lancet</i> , The, 2022, 399, 629-655.	13.7	4,915
2	Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. <i>New England Journal of Medicine</i> , 2018, 378, 911-923.	27.0	226
3	Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 245-252.	2.1	68
4	Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. <i>New England Journal of Medicine</i> , 2021, 385, 2531-2543.	27.0	57
5	Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. <i>Infection, Genetics and Evolution</i> , 2007, 7, 333-342.	2.3	56
6	Raltegravir Pharmacokinetics During Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 375-381.	2.1	56
7	Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. <i>Archives of Disease in Childhood</i> , 2020, 105, 26-31.	1.9	56
8	Pharmacokinetics of tenofovir during pregnancy and postpartum. <i>HIV Medicine</i> , 2015, 16, 502-511.	2.2	50
9	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 72-77.	2.1	50
10	Infant Growth Outcomes After Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 374-381.	2.1	49
11	Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. <i>Aids</i> , 2005, 19, 1495-1499.	2.2	45
12	Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 33-41.	2.1	41
13	Response to planned treatment interruptions in HIV infection varies across childhood. <i>Aids</i> , 2010, 24, 231-241.	2.2	38
14	Pharmacokinetic Optimization of Antiretroviral Therapy in Pregnancy. <i>Clinical Pharmacokinetics</i> , 2012, 51, 639-659.	3.5	38
15	Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 289-296.	2.1	38
16	Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. <i>Aids</i> , 2020, 34, 255-260.	2.2	38
17	Predictors of 5-Year Mortality in HIV-Infected Adults Starting Highly Active Antiretroviral Therapy in Thailand. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 91-98.	2.1	36
18	Plasma efavirenz concentrations and the association with CYP2B6*516 G >T polymorphism in HIV-infected Thai children. <i>Antiviral Therapy</i> , 2009, 14, 315-320.	1.0	36

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics of an Increased Atazanavir Dose With and Without Tenofovir During the Third Trimester of Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 59-66.	2.1	35
20	Switching HIV Treatment in Adults Based on CD4 Count Versus Viral Load Monitoring: A Randomized, Non-Inferiority Trial in Thailand. <i>PLoS Medicine</i> , 2013, 10, e1001494.	8.4	35
21	Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 1005-1012.	2.4	34
22	Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 283-8.	2.1	32
23	Development of a one-step immunochromatographic strip test for the rapid detection of nevirapine (NVP), a commonly used antiretroviral drug for the treatment of HIV/AIDS. <i>Talanta</i> , 2007, 71, 462-470.	5.5	31
24	Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. <i>Antiviral Therapy</i> , 2011, 16, 1287-1295.	1.0	31
25	Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1265-1273.	3.0	29
26	Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. <i>BMC Infectious Diseases</i> , 2016, 16, 393.	2.9	29
27	Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 36-48.	4.7	29
28	The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection. <i>PLoS ONE</i> , 2013, 8, e76582.	2.5	29
29	A Chewable Pediatric Fixed-dose Combination Tablet of Stavudine, Lamivudine, and Nevirapine. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 940-944.	2.0	28
30	Efficacy and Safety of 1-Month Postpartum Zidovudine/Didanosine to Prevent HIV-Resistance Mutations after Intrapartum Single-Dose Nevirapine. <i>Clinical Infectious Diseases</i> , 2010, 50, 898-908.	5.8	28
31	Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. <i>Lancet HIV</i> , 2019, 6, e623-e631.	4.7	27
32	Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-36 months. <i>Antiviral Therapy</i> , 2010, 15, 297-305.	1.0	26
33	Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. <i>Clinical Infectious Diseases</i> , 2017, 64, 1597-1603.	5.8	26
34	ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. <i>BMC Infectious Diseases</i> , 2021, 21, 5.	2.9	26
35	Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 1041-1044.	3.0	25
36	Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. <i>Aids</i> , 2010, 24, 2193-2200.	2.2	25

#	ARTICLE	IF	CITATIONS
37	Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. <i>Aids</i> , 2013, 27, 579-589.	2.2	24
38	Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). <i>Clinical Infectious Diseases</i> , 2020, 70, 2143-2151.	5.8	24
39	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. <i>Pharmacogenomics</i> , 2012, 13, 1501-1522.	1.3	23
40	Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 61, 95-101.	5.8	23
41	Efficacy, Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Virologic-Suppressed HIV-infected Children Using Weight-Band Dosing. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 392-397.	2.0	23
42	Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at risk for HIV in Thailand: a randomized control trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25564.	3.0	23
43	Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. <i>Antiviral Therapy</i> , 2009, 14, 315-20.	1.0	23
44	Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5374-5380.	3.2	21
45	New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 453-459.	2.1	20
46	A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. <i>BMC Infectious Diseases</i> , 2017, 17, 496.	2.9	20
47	Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. <i>European Journal of Cancer</i> , 2002, 38, 586-593.	2.8	19
48	A Comparison of 3 Regimens to Prevent Nevirapine Resistance Mutations in HIV-Infected Pregnant Women Receiving a Single Intrapartum Dose of Nevirapine. <i>Clinical Infectious Diseases</i> , 2012, 54, 285-293.	5.8	19
49	The role of formulation on the pharmacokinetics of antiretroviral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1019-1037.	3.3	19
50	Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention. <i>Current HIV/AIDS Reports</i> , 2020, 17, 487-498.	3.1	19
51	Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2019, 69, 144-146.	5.8	18
52	Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse-Transcriptase Inhibitors in HIV Type 1-Infected Children. <i>Clinical Infectious Diseases</i> , 2008, 46, 1601-1608.	5.8	16
53	Reduced indinavir exposure during pregnancy. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 475-483.	2.4	16
54	Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1185-1194.	3.5	16

#	ARTICLE	IF	CITATIONS
55	Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1433-1450.	3.5	16
56	Efavirenz pharmacokinetics during pregnancy and infant washout. <i>Antiviral Therapy</i> , 2018, 24, 95-103.	1.0	15
57	Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial. <i>PLoS ONE</i> , 2018, 13, e0196239.	2.5	15
58	Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPACT P1093): results of an open-label, phase 1 trial. <i>Lancet HIV</i> , 2022, 9, e332-e340.	4.7	15
59	Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 347-361.	3.3	14
60	Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol. <i>Clinical Infectious Diseases</i> , 2017, 65, 982-989.	5.8	14
61	Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 83-93.	3.1	14
62	Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	14
63	Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. <i>Clinical Pharmacokinetics</i> , 2021, 60, 795-809.	3.5	14
64	Intensive Pharmacokinetics of Zidovudine 200 mg Twice Daily in HIV-1-Infected Patients Weighing Less Than 60 kg on Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 387-389.	2.1	13
65	Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults. <i>Malaria Journal</i> , 2015, 14, 400.	2.3	13
66	Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand. <i>Aids</i> , 2015, 29, 2497-2507.	2.2	13
67	Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 448-458.	8.1	13
68	Developmental Pharmacokinetic Changes of Lamivudine in Infants and Children. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1824-1832.	2.0	12
69	Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment. <i>Clinical Infectious Diseases</i> , 2015, 61, 633-639.	5.8	12
70	Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 554-560.	2.1	12
71	Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz298.	0.9	12
72	EFFICACY AND PLASMA CONCENTRATIONS OF INDINAVIR WHEN BOOSTED WITH RITONAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED THAI CHILDREN. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 86-88.	2.0	11

#	ARTICLE	IF	CITATIONS
73	Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 431-443.	2.0	11
74	Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	11
75	Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV. <i>PLoS ONE</i> , 2015, 10, e0126647.	2.5	11
76	No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, e56-e59.	2.1	10
77	Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 1383-1390.	1.4	10
78	Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 217-224.	3.0	10
79	Incidence and clinical outcomes of diabetes mellitus in HIV-infected adults in Thailand: a retrospective cohort study. <i>BMC Public Health</i> , 2018, 18, 1079.	2.9	10
80	Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. <i>International Journal of Infectious Diseases</i> , 2020, 97, 365-370.	3.3	10
81	Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 72, 2032-2034.	5.8	10
82	Advancing the prevention and treatment of HIV in children: priorities for research and development. <i>Lancet HIV</i> , 2022, 9, e658-e666.	4.7	10
83	Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption. <i>Aids</i> , 2016, 30, 1075-1081.	2.2	9
84	Brief Report: AIDS-Defining Events and Deaths in HIV-Infected Children and Adolescents on Antiretrovirals: A 14-Year Study in Thailand. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 17-22.	2.1	9
85	Semi-quantification of HIV-1 protease inhibitor concentrations in clinical samples of HIV-infected patients using a gold nanoparticle-based immunochromatographic assay. <i>Analytica Chimica Acta</i> , 2019, 1071, 86-97.	5.4	9
86	Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab200.	0.9	9
87	A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2022, 10, e25561.	3.7	9
88	Pharmacokinetics of Pediatric Lopinavir/Ritonavir Tablets in Children When Administered Twice Daily According to FDA Weight Bands. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 301-305.	2.0	8
89	Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2016, 5, 131-137.	1.3	8
90	A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, e29-e35.	2.0	8

#	ARTICLE	IF	CITATIONS
91	Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1348-1356.	3.0	8
92	One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 9-10.	5.6	8
93	Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 324-331.	2.1	8
94	Immunochemical Strip Test for Rapid Detection of Nevirapine in Plasma Samples from Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3361-3363.	3.2	7
95	Comparison of the TaqMan and LightCycler systems in evaluation of CYP2B6 516G>T polymorphism. <i>Molecular and Cellular Probes</i> , 2007, 21, 408-411.	2.1	7
96	Pharmacokinetics of Nevirapine in HIV and Tuberculosis-coinfected Children Receiving Antiretroviral Fixed-dose Combination Tablets While Receiving Rifampicin-containing Tuberculosis Treatment and After Rifampicin Discontinuation. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 389-391.	2.0	7
97	Does pregnancy affect the pharmacokinetics of efavirenz?. <i>Aids</i> , 2014, 28, 1542-1543.	2.2	7
98	Efavirenz Concentrations and Probability of HIV Replication in Children. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1214-1217.	2.0	7
99	Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, S40-S48.	2.1	7
100	Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 1081-1086.	2.0	7
101	Simplifying TREATment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. <i>BMJ Open</i> , 2021, 11, e050116.	1.9	7
102	Early Postpartum Pharmacokinetics of Lopinavir Initiated Intrapartum in Thai Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2189-2191.	3.2	6
103	Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children. <i>AIDS and Behavior</i> , 2013, 17, 193-202.	2.7	6
104	Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e271-e274.	2.0	6
105	Expedient screening for HIV-1 protease inhibitors using a simplified immunochromatographic assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1021, 153-158.	2.3	6
106	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400Ång in Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1421-1433.	3.5	6
107	Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. <i>Lancet HIV</i> , 2022, 9, e24-e31.	4.7	6
108	Influence of Body Weight on Achieving Indinavir Concentrations Within Its Therapeutic Window in HIV-Infected Thai Patients Receiving Indinavir Boosted With Ritonavir. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 25-31.	2.0	5

#	ARTICLE	IF	CITATIONS
109	Pilot evaluation of an enzymatic assay for rapid measurement of antiretroviral drug concentrations. <i>Virology Journal</i> , 2021, 18, 77.	3.4	5
110	What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies. <i>Lancet HIV</i> , 2022, 9, e649-e657.	4.7	5
111	Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 490-495.	3.0	4
112	Incidence of Tuberculosis and Associated Mortality in a Cohort of Human Immunodeficiency Virus-Infected Children Initiating Antiretroviral Therapy. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, 161-167.	1.3	4
113	Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1045-1050.	2.0	4
114	Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 388-393.	2.0	4
115	Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2927-2931.	3.0	3
116	Pharmacological Assessment of Efavirenz Weight-Band Dosing Recommendations in HIV-Infected Thai Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, e27-e29.	2.1	3
117	Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 313-322.	2.1	3
118	Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1041-1045.	3.0	3
119	Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. <i>BMC Medical Research Methodology</i> , 2022, 22, 49.	3.1	3
120	Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children. <i>HIV Medicine</i> , 2014, 15, 511-512.	2.2	2
121	Contribution of Different Antiretroviral Regimens Containing Zidovudine, Lamivudine and Ritonavir-Boosted Lopinavir on HIV Viral Load Reduction during Pregnancy. <i>Antiviral Therapy</i> , 2016, 21, 435-440.	1.0	2
122	Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children. <i>Journal of Virus Eradication</i> , 2015, 1, 185-191.	0.5	2
123	Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1333-1335.	2.0	2
124	Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 152-156.	2.0	2
125	Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children. <i>HIV Medicine</i> , 2021, 22, 172-184.	2.2	2
126	Lack of Association between Adverse Pregnancy Outcomes and Zika Antibodies among Pregnant Women in Thailand between 1997 and 2015. <i>Viruses</i> , 2021, 13, 1423.	3.3	2



#	ARTICLE	IF	CITATIONS
127	Pharmacogenomics and the prevention of mother-to-child transmission of HIV. <i>Pharmacogenomics</i> , 2010, 11, 1-4.	1.3	1
128	Pharmacokinetics of Rilpivirine and 24-Week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-Infected Adolescents. <i>Antiviral Therapy</i> , 2018, 23, 259-265.	1.0	1
129	Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 443-445.	0.4	1
130	Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children. <i>PLoS ONE</i> , 2019, 14, e0216868.	2.5	1
131	Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 996-999.	3.0	1
132	A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based Regimens. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1076-1083.	2.0	0
133	Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults: Table 1.. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, piw017.	1.3	0
134	Serum Theophylline Concentrations in very Preterm Neonates Receiving Intravenous Aminophylline for Apnea. <i>Siriraj Medical Journal</i> , 2021, 73, 526-531.	0.3	0
135	Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children. <i>Journal of Virus Eradication</i> , 2015, 1, 185-91.	0.5	0